

IN brief**Myriad wins *BRCA1* row**

After seven years of dispute, the European Patent Office (EPO) has decided to uphold Myriad Genetics' patent on the *BRCA1* 'breast cancer gene' but in a limited form. In 2001 patents were granted to Salt Lake City, Utah-based Myriad for using the genes *BRCA1* and *BRCA2* to diagnose women's predisposition to breast and ovarian cancers. But international research institutes and genetics societies filed an opposition to the patents. "It became clear that the patent owners did not intend to offer licenses [to other institutions], or at least not at a reasonable price," says Gert Mattheij from the Center for Human Genetics, University of Leuven, Belgium. "This [pricing issue] has angered the genetic community, even more than the idea that genes and diagnostic tests could be patented." As a result, EPO revoked the patent for *BRCA1*. Myriad then filed an appeal requesting that the patent be maintained in a revised form. The November 19 ruling gives the patent owners the right to collect royalties on tests carried out across Europe, although the patent's original scope has been reduced to cover only frameshift mutations, not *BRAC1* itself. EPO says the patent cannot be contested at the European level; however, it is still possible for opponents to go to national courts to further reduce the scope of the patent. Myriad's William Hockett says the company is pleased with EPO's decision.

—Nayanah Siva

Value-driven price deal

Small companies and patients stand to benefit from the recently renegotiated Pharmaceutical Price Regulation Scheme (PPRS). Rather than the 5% across-the-board price cut to medicines proposed in June, the finalized deal recommends a pricing scheme that staggers and delays price cuts. PPRS is a voluntary agreement between government and industry on pricing of branded drugs supplied to the National Health Service (NHS). The finalized PPRS recommends a 3.9% price cut in February, followed by a 1.9% cut in January 2010, and for small companies with sales up to £25 (\$37.5) million in 2007, the first £5 (\$7.5) million sales will be exempt from the price cut. For the first time, the UK's Bioindustry Association (BIA) has been involved in PPRS negotiations, working closely with the Association of British Pharmaceutical Industry on aspects affecting small companies. As part of the agreement, companies that supply the NHS will be allowed to introduce drugs at lower initial prices with the option of negotiating higher prices at later stages if the clinical value of a product is proved. This flexible pricing scheme agreed upon in November will ensure patients have faster access to novel medicines, and encourage industry innovation. "This is a definite plus," says Nick Scott-Ram, the BIA's strategy consultant on this issue. "The PPRS is now taking a more value-based approach to everything. We have come out of 18 months of negotiation in a reasonable position."

—Susan Aldridge

Pediatric Multiple Sclerosis Comprehensive Care Center, who is nonetheless guardedly optimistic. "You have patients with relapses and remissions. If you get rid of the relapses, then over time, it's going to look like there is less [of a] persistent neurologic deficit. It's just a function of the drug's effects on the relapses, rather than turning the disease around."

The claims of disease reversal regarding Campath are still "a big stretch," says Wolinsky, who points out that the extrapolations are made by hopeful onlookers and boosters and not by the drug makers Genzyme and Bayer Schering. "The absolute good news is, if we treat early and aggressively, we can expect remarkable outcomes, but at a cost for a fair percentage of patients."

Clinicians and regulators worry over side effects, particularly the risk of developing a rare neurological condition progressive multifocal leukoencephalopathy (PML), the brain infection that bedevils the α -4 integrin antagonist Tysabri (natalizumab), co-marketed by Biogen Idec, of Cambridge, Massachusetts, and Dublin-based Elan. Thus far, no cases of PML have shown up in MS patients exposed to Campath. Years of experience using Campath for chronic lymphocytic leukemia treatment may not be informative as patients with this form of leukemia can develop PML, independently of Campath.

Despite the troubles associated with Tysabri, people with MS may still retain "an overall positive view" toward the treatment, says David Williams, head of business development for PatientsLikeMe, an online health community for patients with life-changing conditions including MS. "Campath will be the same way, if it's approved," Williams predicts, though the risks as known so far are hardly identical.

With Campath, safety issues could arise over a potentially fatal autoimmune disorder. In the phase 2 trials, 20% of Campath-treated patients developed thyroid disorders compared to 3% on Rebif. Krupp notes, however, that thyroid trouble seems to occur with MS anyway, for reasons that are not well understood. More serious is the development of immune thrombocytopenic purpura (ITP). Three patients in the Campath group developed this complication and one of them died. "Some people would suggest management

of ITP is easy, but if it were straightforward and easy, they wouldn't have had the first one die," Wolinsky says. Margolin notes that the fatal case of ITP—the first to arise—"took everyone by surprise," whereas the others fully recovered with treatment, and one did so spontaneously. Krupp, for her patients, "would consider [Campath] in patients where all of those things, as bad as they sound, are 'not as bad' as what's happening with their MS."

Other promising mAbs in late-stage development for MS include Rituxan (rituximab), an approved therapy for rheumatoid arthritis and non-Hodgkin's lymphoma from Biogen and S. San Francisco, California-based Genentech, in phase 3 trials (**Table 1**). Another drug currently in phase 2 studies is Zenapax (daclizumab), an immunosuppressant mAb for

organ transplants from Biogen and PDL Biopharma of Fremont, California. Leerink Swann analyst William Tanner wrote in a September research report that consultants were "not overly impressed" with Zenapax, holding out hopes for other compounds, though the safety profile of Campath may be of concern. Still in the game, but just barely, is Basel-based Novartis' S1P1 modulator FTY720 (fingolimod), which has run into serious safety issues in pivotal testing.

For Campath, efficacy could win over safety concerns. One phase 3 trial aims to enroll 525 patients like those in phase 2 with early, relapsing, remitting disease; the other will test relapsing MS patients and intends to enroll 1,200. Campath could be filed for approval with the FDA as early as 2011, probably as a monotherapy. "With the findings to date, I don't see any reason to add another drug," Margolin says, though some neurologists speculate that Campath might be used as induction therapy, to be followed by interferon or Copaxone (glatiramer).

An ongoing debate in MS therapy is how the disease's inflammatory and neurodegenerative aspects overlap and what this means for drug developers. "None of these drugs are going to fix neurons that are dead and gone, but some probably will help to slow the neurodegenerative processes," Margolin says. "We hope our trials will establish Campath as the treatment of choice, if patients are relapsing."

Randy Osborne Mill Valley, California